A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology (Durasert E™) for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU™1, is an investigational sustained delivery treatment for vascular endothelial growth factor (VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI) with the Company's bioerodible Durasert E™ drug delivery technology. DURAVYU is currently being evaluated in Phase 3 pivotal trials (LUGANO and LUCIA) for wet age-related macular degeneration (wet AMD) and in Phase 3 clinical trials (COMO and CAPRI) for diabetic macular edema (DME).
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | 46M | - | 37M |
| Net Income | -232M | -232M | -131M | -71M | -102M | -58M |
| EPS | $-3.17 | $-3.17 | $-2.32 | $-1.82 | $-2.74 | $-2.03 |
| Free Cash Flow | -243M | -243M | -130M | -1.6M | -67M | -50M |
| ROIC | -85.4% | -72.2% | -38.9% | -23.9% | -81.4% | -26.4% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.07 | 0.07 | 0.06 | 0.13 | 0.48 | 0.21 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -243M | -243M | -146M | -75M | -100M | -55M |
| Operating Margin | 0.0% | - | - | -163.1% | - | -149.6% |
| ROE | -75.8% | -72.2% | -38.9% | -26.6% | -106.1% | -31.7% |
| Shares Outstanding | 73M | 73M | 56M | 39M | 37M | 29M |
EyePoint, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
EyePoint, Inc. (EYPT) has a 5-year average return on invested capital (ROIC) of -48.6%. This is below average and may indicate limited pricing power.
EyePoint, Inc. (EYPT) has a market capitalization of $1.1B. It is classified as a small-cap stock.
EyePoint, Inc. (EYPT) does not currently pay a regular dividend.
EyePoint, Inc. (EYPT) operates in the Laboratory Analytical Instruments industry, within the Technology sector.
EyePoint, Inc. (EYPT) generated $-243 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
EyePoint, Inc. (EYPT) has a debt-to-equity ratio of 0.07. This indicates a conservatively financed balance sheet.
EyePoint, Inc. (EYPT) reported earnings per share (EPS) of $-3.17 in its most recent fiscal year.
EyePoint, Inc. (EYPT) has a return on equity (ROE) of -72.2%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 16 years of financial data for EyePoint, Inc. (EYPT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
EyePoint, Inc. (EYPT) has a book value per share of $4.18, based on its most recent annual SEC filing.